{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-013788","form_type":"8-K","ticker":"XTNT","cik":"0001453593","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2026-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.112489+00:00","generated_at":"2026-05-15T08:08:35.101575+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Xtant Medical reports FY2025 net income $5.0M vs loss $16.5M; revenue $134M (+14% YoY)","bullets":["Full-year 2025 revenue $134.0M (+14% YoY); net income $5.0M ($0.03 diluted EPS) vs net loss $16.5M in 2024.","Q4 2025 revenue $32.4M (+3% YoY); net income $0.1M vs net loss $3.2M; non-GAAP adjusted EBITDA $1.9M vs $0.4M.","Completed sale of non-core Coflex/CoFix assets and international hardware to Companion Spine for $21.4M cash.","Launched nanOss Strata synthetic bone graft and CollagenX bovine collagen product; total cash $17.3M at Dec 2025 + $10.5M received Feb 2026.","FY2026 revenue guidance $95M-$99M reflecting divestiture impact and cessation of license revenue; expects free cash flow positive."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-013788","json":"https://secwatch.observer/filing/0001493152-26-013788.json","markdown":"https://secwatch.observer/filing/0001493152-26-013788.md","text":"https://secwatch.observer/filing/0001493152-26-013788.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1453593/000149315226013788/0001493152-26-013788-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1453593/000149315226013788/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:08:35.101575+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3822601bcbf0d73a083746c5acec9ef7d576353d","claim":"Xtant Medical Holdings, Inc. reported Fourth Quarter 2025 results: revenue $32.4 million, net income $0.1 million.","evidence_excerpt":"Fourth quarter 2025 revenue grew 3% to $32.4 million, compared to $31.5 million for the same period in 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315226013788/0001493152-26-013788-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Fourth Quarter 2025"},{"label":"Revenue","value":"$32.4 million"},{"label":"Net income","value":"$0.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"e0fbf94fbcdd878b7e010e508ee388808fcdbc5c","claim":"Xtant Medical Holdings, Inc. reported Full Year 2025 results: revenue $134.0 million, net income $5.0 million, EPS $0.03 per diluted share.","evidence_excerpt":"and may be different from non-GAAP finan --- EX-99.1 (EX-99.1) --- Xtant Medical Reports Fourth Quarter and Full-Year 2025 Financial Results Full year 2025 revenue totals $133.9 million, an increase of 14% year-over-year Xtant delivers positive net income, adjusted EBITDA and operating cash flow Total cash of $17.3 million as of December 31, 2025 with an","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315226013788/0001493152-26-013788-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full Year 2025"},{"label":"Revenue","value":"$134.0 million"},{"label":"Net income","value":"$5.0 million"},{"label":"EPS","value":"$0.03 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}